title: A structural biology view of target drugability.
abstract: BACKGROUND
  With long and costly drug development times there is a need in the pharmaceutical industry to prioritize targets early in the drug discovery process. One of the possible criteria is 'protein drugability', a term with multiple understandings in the literature. Among others, it is the likelihood of finding a selective, low-molecular weight molecule that binds with high affinity to the target.
  
  
  OBJECTIVE
  Which methods are available for drugability prediction? What can be achieved by such predictions and how can they influence the target prioritization process?
  
  
  METHODS
  The main focus is on sequence- and structure-related computational methods for drugability prediction, giving an overview on their background as well as their bias and limitations with an emphasis on the structural biology point of view.
  
  
  CONCLUSIONS
  Structural drugability assessment presents one criterion for prioritization of a target portfolio by enabling classification of targets into low, average, or high drugability.
authors.affiliation: Head of Structural Biology Bayer Schering Pharma AG, Lead Discovery Berlin - Structural Biology, 13342 Berlin, Germany +49 30 46811522 ; +49 30 46891522 ; Ursula.Egner@bayerhealthcare.com.
authors.forename: Ursula
authors.initials: U
authors.lastname: Egner
authors.forename: Roman C
authors.initials: RC
authors.lastname: Hillig